FUSEN PHARM (01652): Four products are expected to win bids in the national centralized drug procurement.
Fosen Pharmaceutical (01652) announced that in the twelfth round of the national centralized procurement bidding in China on July 31, 2026, four of the company's products are expected to win bids: Nicardipine Injection (2ml: 2mg, 5ml: 5mg), Methylaspartate Potassium Tablets (40mg, 80mg), Compound Potassium Hydrogen Phosphate Injection (5ml: Dihydrogen Phosphate Potassium 1.12g and Hydrogen Phosphate Potassium (calculated as K2HPO4) 1.18g), Dydrogesterone Tablets (10mg).
FUSEN PHARM (01652) announced that in the twelfth round of the national centralized procurement tender in China on July 31, 2026, four of the company's products are expected to win bids: Nicardipine Injection (2ml: 2mg, 5ml: 5mg), Mesalazine Potassium Tablets (40mg, 80mg), Compound Potassium Dihydrogen Phosphate Injection (5ml: Dihydrogen Potassium Phosphate 1.12g and Dipotassium Hydrogen Phosphate (calculated as K2HPO4) 1.18g), and Dydrogesterone Tablets (10mg).
Related Articles
XD INC (02400) spent approximately HKD 4.7592 million on August 3 to repurchase 100,000 shares.
WKK INTL (HOLD)(00532): Wang Zhongtong has been transferred to the position of non-executive director.
GAUSH MEDITECH (02407) expects revenue in the first half of the year to decrease by approximately 7.1% year-on-year to 10.7%.
XD INC (02400) spent approximately HKD 4.7592 million on August 3 to repurchase 100,000 shares.
WKK INTL (HOLD)(00532): Wang Zhongtong has been transferred to the position of non-executive director.
GAUSH MEDITECH (02407) expects revenue in the first half of the year to decrease by approximately 7.1% year-on-year to 10.7%.
RECOMMEND
